A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb14045 in Patients With CD123-Expressing Hematologic Malignancies

Trial Profile

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb14045 in Patients With CD123-Expressing Hematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs XmAb 14045 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; First in man
  • Sponsors Xencor
  • Most Recent Events

    • 10 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2019.
    • 03 Oct 2016 Planned number of patients changed from 60 to 66.
    • 12 Sep 2016 According to a Xencor media release, first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top